MedTrace Logo

Airtime Incentive Amounts to Improve Interactive Voice Response Surveys in Bangladesh and Uganda

NCT03768323 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 4233

Last updated 2018-12-10

No results posted yet for this study

Summary

This study evaluates the effect of two different airtime incentive amounts on interactive voice response (IVR) survey cooperation, response, refusal, and contact rates, as compared to control group, in Bangladesh and Uganda.

Conditions

  • Surveys and Questionnaires
  • Noncommunicable Diseases

Interventions

OTHER

1X airtime incentive

an incentive given in the form of airtime to motivate participants to complete the survey. Participants were given 50 Bangladeshi Taka ($0.60 USD) or 5000 Ugandan Shillings (UGX; $1.35 USD as of April 3, 2018) worth of airtime for completing the survey

OTHER

2X airtime incentive

an incentive given in the form of airtime to motivate participants to complete the survey. Participants were given 100 Bangladeshi Taka ($1.20 USD) or 10000 UGX ($2.70 USD) worth of airtime for completing the survey

Sponsors & Collaborators

  • The Bloomberg Family Foundation, Inc.

    collaborator OTHER

  • Makerere University

    collaborator OTHER

  • Institute of Epidemiology, Disease Control and Research

    collaborator OTHER

  • Johns Hopkins Bloomberg School of Public Health

    lead OTHER

Principal Investigators

  • Adnan A Hyder, Phd, MBBS · Johns Hopkins Bloomberg School of Public Health

  • George W Pariyo, PhD · Johns Hopkins University Bloomberg School of Public Health

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-03-26
Primary Completion
2017-07-14
Completion
2017-07-14

Countries

  • Bangladesh
  • Uganda

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03768323 on ClinicalTrials.gov